Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route (Ascending) Package Effective Date Package Discontinuation Date Status
63323-0194-05 63323-0194 Idarubicin Hydrochloride Idarubicin Hydrochloride 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 11, 2009 In Use
63323-0194-10 63323-0194 Idarubicin Hydrochloride Idarubicin Hydrochloride 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 11, 2009 In Use
63323-0194-20 63323-0194 Idarubicin Hydrochloride Idarubicin Hydrochloride 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 11, 2009 In Use
00143-9531-01 00143-9531 Ifosfamide Ifosfamide 50.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 10, 2017 In Use
63323-0142-10 63323-0142 Ifosfamide Ifosfamide 1.0 g/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Jan. 28, 2003 In Use
63323-0142-12 63323-0142 Ifosfamide Ifosfamide 1.0 g/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Jan. 28, 2003 In Use
00008-0100-01 00008-0100 Inotuzumab Ozogamicin Besponsa 0.25 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous Aug. 18, 2017 In Use
62756-0093-40 62756-0093 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 7, 2012 Jan. 31, 2017 No Longer Used
62756-0093-44 62756-0093 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Aug. 31, 2012 Jan. 31, 2017 No Longer Used
62756-0094-40 62756-0094 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 7, 2012 Nov. 30, 2016 No Longer Used
62756-0094-44 62756-0094 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Aug. 31, 2012 Nov. 30, 2016 No Longer Used
62756-0095-40 62756-0095 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 7, 2012 Nov. 30, 2016 No Longer Used
62756-0095-44 62756-0095 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Aug. 31, 2012 Nov. 30, 2016 No Longer Used
00069-0293-10 00069-0293 filgrastim-aafi Nivestym 300.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous March 11, 2019 In Use
00069-0294-10 00069-0294 filgrastim-aafi Nivestym 480.0 ug/1.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous March 11, 2019 In Use
00409-2504-10 00409-2504 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Nov. 14, 2018 In Use
00781-3415-75 00781-3415 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Nov. 26, 2018 In Use
43598-0771-11 43598-0771 LEVOLEUCOVORIN LEVOLEUCOVORIN 175.0 mg/17.5mL Ancillary Therapy Chemoprotective Antidote Intravenous Sept. 26, 2018 In Use
43598-0773-11 43598-0773 LEVOLEUCOVORIN LEVOLEUCOVORIN 250.0 mg/25mL Ancillary Therapy Chemoprotective Antidote Intravenous Sept. 26, 2018 In Use
55150-0186-05 55150-0186 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Nov. 6, 2018 In Use
63323-0673-05 63323-0673 Palonosetron Palonosetron 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sept. 19, 2018 In Use
63323-0673-89 63323-0673 Palonosetron Palonosetron 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sept. 19, 2018 In Use
67184-0514-01 67184-0514 Palonosetron Hydrochloride Palonosetron 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sept. 19, 2018 In Use
67184-0515-02 67184-0515 Palonosetron Hydrochloride Palonosetron 0.075 mg/1.5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sept. 19, 2018 In Use
67457-0317-25 67457-0317 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sept. 20, 2018 In Use

Found 10,000 results in 4 millisecondsExport these results